文献速递消化与肝胆胰病理细胞病理与分子病理

胰腺胆管细胞病理报告系统风险分层的3年前瞻性单中心经验更新

Update on risk stratification in the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology categories: 3-Year, prospective, single-institution experience.
PubMed 文献 · Cancer Cytopathol · 2019-11-13

该研究基于单中心3年前瞻性数据,评估胰腺胆管细胞病理报告系统(PSCPC)各分类的恶性风险(ROM)和总体恶性风险(OROM)。共1017例胰腺FNA,548例有随访,各分类ROM与OROM存在差异,结论认为良性及不确定分类的真实ROM可能介于ROM与OROM之间,且识别高级别异型增生对恶性风险分层重要。

要点

  • PSCPC各分类ROM:I 25%、II 17.4%、III 41.8%、IV良性 0%、IV其他 34.3%、V 95.5%、VI 99.6%。
  • OROM:I 4.5%、II 2.5%、III 25.3%、IV良性 0%、IV其他 27.1%、V 75%、VI 87.9%。
  • IV其他分类中识别高级别异型增生与恶性及更高ROM相关。

核心结论

  • 良性及不确定分类的真实ROM可能介于ROM与OROM之间。
  • 在IV其他分类中识别高级别异型增生对恶性风险分层重要。

研究设计与样本

  • 共1017例胰腺FNA,其中548例有手术和/或临床随访数据。

主要发现

  • 各分类病例数:I 242例、II 162例、III 142例、IV良性 20例、IV其他 133例、V 28例、VI 290例。
  • 各分类恶性例数:I 11例、II 4例、III 36例、IV良性 0例、IV其他 36例、V 21例、VI 255例。
  • ROM分别为25%、17.4%、41.8%、0%、34.3%(95.2%)、95.5%、99.6%。
  • OROM分别为4.5%、2.5%、25.3%、0%、27.1%(83.3%)、75%、87.9%。

临床怎么用

  • 可参考PSCPC各分类的ROM与OROM进行风险分层沟通。
  • 对IV其他分类应关注高级别异型增生以评估恶性风险。

局限性

  • 单中心经验,随访数据仅覆盖548/1017例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk stratification is a critical element for the successful implementation of cytopathology reporting systems. To the authors' knowledge, there are limited prior studies regarding risk stratification for The Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology (PSCPC). In the current study, the authors reported on a single-institution experience on 3-year prospective PSCPC regarding risk of malignancy (ROM) and the overall risk of malignancy (OROM). METHODS: A computerized search was performed from August 2014 to December 2017 for all pancreatic fine-needle aspiration (FNA) samples. Pathology from surgical resections and biopsies and relevant radiologic and clinical follow-up data were collected. The ROM and the OROM were calculated. The OROM was based on the total number of FNA samples in each category. RESULTS: A total of 1017 pancreatic FNA cases were identified, with surgical and/or clinical follow-up data available for 548 cases. The cytopathologic diagnoses included 242 nondiagnostic (category I), 162 benign (category II), 142 atypical (category III), 20 neoplastic-benign (category IV: benign), 133 neoplastic-other (category IV: other), 28 suspicious (category V), and 290 malignant (category VI) cases. A total of 364 malignancies were documented in 11 cases, 4 cases, 36 cases, 0 cases, 36 cases, 21 cases, and 255 cases, respectively, from categories I, II, III, IV: benign, IV:other, V, and VI. The ROM was 25%, 17.4%, 41.8%, 0%, 34.3% (95.2%), 95.5%, and 99.6%, respectively, and the OROM was 4.5%, 2.5%, 25.3%, 0%, 27.1% (83.3%), 75%, and 87.9%, respectively, for categories I, II, III, IV: benign, IV: other (with high-grade dysplasia), V, and VI. CONCLUSIONS: The true ROM for PSCPC is likely between the ROM and OROM for the benign and indeterminate categories. In the neoplastic-other category (category IV: other), identifying high-grade dysplasia is important for its association with malignancy and a higher ROM.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Sung S, Del Portillo A, Gonda TA, et al. Update on risk stratification in the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology categories: 3-Year, prospective, single-institution experience. Cancer Cytopathol. 2019. PMID: 31722125. doi:10.1002/cncy.22199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。